Chelsea Therapeutics International

About:

Chelsea Therapeutics International is a pharmaceutical company developing and commercializing therapeutics for a variety of human diseases.

Website: http://chelseatherapeutics.com

Top Investors: Venrock, Paramount BioCapital Asset Management

Description:

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), and related conditions and diseases along with its development of prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease and cancer. As of December 31, 2009, it was focused on its drug development resources on two clinical stage development projects: droxidopa for symptomatic NOH and other potential indications, and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis.

Total Funding Amount:

$63M

Headquarters Location:

Charlotte, North Carolina, United States

Founded Date:

2004-01-01

Contact Email:

webemail06(AT)chelseatherapeutics.com

Founders:

Simon Pedder

Number of Employees:

11-50

Last Funding Date:

2013-11-18

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai